Tuberculosis as a Complication of BCG in the Treatment of Bladder Carcinoma: Tuberculosis as a Complication of BCG in the Treatment of Bladder Carcinoma

Hiba Adnan Hameed, National Tuberculosis Institute. Baghdad, Iraq.Follow
Mohammad Yahya Abdulrazaq, National Tuberculosis Institute. Baghdad, Iraq.Follow
Abass Farhood Hussein, National Tuberculosis Institute. Baghdad, Iraq.Follow

Article Type

Original Study

Subject

pulmonology

Abstract

Bacillus Calmette-Guérin (BCG), is a live attenuated strain of Mycobacterium bovis, and is the essential constituent of the vaccine against tuberculosis (TB) and adjuvant treatment for bladder cancer. This vaccine has a potential pathogenic action; bacilli can cause recorded complications that can be located locally near the site of inoculation and at a distance through blood dissemination root. The BCG-related disease can represent a side effect of anti-TB vaccination in patients with acquired or congenital immunodeficiency or a complication of the therapeutic oncologic schedule in patients with malignancy. Here in we report three cases of BCG-related disease which visited our national tuberculosis Iraqi center in 2022, two of those with locally developed TB and the third presented with disseminated miliary TB.

Keywords

BCG, Extra-pulmonary Tuberculosis, Miliary TB, Bladder carcinoma

Recommended Citation

Hameed, Hiba Adnan; Abdulrazaq, Mohammad Yahya; and Hussein, Abass Farhood (2023) "Tuberculosis as a Complication of BCG in the Treatment of Bladder Carcinoma: Tuberculosis as a Complication of BCG in the Treatment of Bladder Carcinoma," Iraqi National Journal of Medicine: Vol. 5 : Iss. 2 , Article 5.
Available at: https://doi.org/10.37319/iqnjm.5.2.1